[用低剂量抗凝剂成功治疗高风险肺栓塞:一个案例报告]
1Department of Pulmonary and Critical Care Medicine, the First Affiliated Hospital of Chongqing Medical University, Chongqing 400016, China.
概括
本案例研究提出了一种新的方法来治疗高风险肺栓塞 (PE),当标准的再注射疗法是禁忌. 一名患有下关节出血的患者使用低剂量抗凝药和血管压缩剂成功康复.
科学领域:
- 心脏病学 心脏病学
- 肺部医学 肺部医学
- 关键护理医学 关键护理医学
背景情况:
- 高风险的肺栓塞 (PE) 通常需要再注射治疗.
- 当血栓溶解禁用,手术或干预疗法无法使用时,治疗选择是有限的.
- 在没有再输血的情况下成功管理高风险PE是具有挑战性的.
研究的目的:
- 报告高风险肺栓塞 (PE) 病例的成功治疗,使用低剂量抗凝剂,当标准再注射方法禁用时.
- 突出复杂PE病例的潜在替代治疗策略.
主要方法:
- 一名56岁的男性患者在下大脑下出血手术后被诊断患有高风险PE.
- 诊断工作包括D-二次体,心肌损伤标志物,心声学和计算机断层扫描肺血管学.
- 治疗涉及低剂量抗凝剂与血管压缩剂相结合,由于血栓溶解的禁忌和拒绝内血管治疗.
主要成果:
- 患者最初处于休克状态,成功地用低剂量抗凝药和血管压缩剂治疗.
- 这种方法导致了高风险肺栓塞的解决.
- 之前没有关于仅用低剂量抗凝剂成功治疗高风险PE的报道.
结论:
- 在特定的临床场景中,低剂量抗凝药与血管压缩剂相结合可能是高风险肺栓塞 (PE) 的可行的治疗方法.
- 这一案例表明,对于那些对标准的再输液疗法有禁忌的患者来说,这是一种潜在的替代方案.
- 需要进一步的研究来探索这种治疗方法在更广泛的患者群体中的有效性和安全性.
相关概念视频
01:30Anticoagulant Drugs: Low-Molecular-Weight Heparins
686
Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
686
01:18Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists
155
Endothelins (ETs) are potent vasoactive peptides critical in the human body's various physiological and pathological processes. One of the most promising therapeutic strategies for treating pulmonary arterial hypertension (PAH) involves counteracting the effects of these endothelins using a class of drugs known as endothelin receptor antagonists.
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
155
01:23Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists
167
Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
167